It is increasingly hard to understand why in Europe we continue to prescribe preserved antiglaucoma therapies for most patients, says Dr Anastasios G.P. Konstas.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
